Research Topics
Species | Morie GertzSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Stem cell transplant for Waldenström macroglobulinemia: an underutilized techniqueM A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Bone Marrow Transplant 47:1147-53. 2012..Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted...- Waldenström macroglobulinemiaMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street, SW, Siebens 667, Rochester, MN 55905, USA
Hematology 17:S112-6. 2012..The current preferred Mayo Clinic non-study treatment is rituximab, cyclophosphamide, and dexamethasone. The median survival associated with this disease is now over 10 years... - Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and managementMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 87:503-10. 2012..MANAGEMENT OF REFRACTORY DISEASE: Bortezomib, thalidomide, lenalidomide, and bendamustine have all been shown to have activity in WM. Given WM's natural history, reduction of complications will be a priority for future treatment trials... 
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trialsMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Oncology (Williston Park) 26:152-61. 2012..Despite advances in the past decade, 30% of patients still die within a year of diagnosis, suggesting that failure to recognize this disorder prior to advanced organ dysfunction remains a major impediment to improving outcomes...- How to manage primary amyloidosisM A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 26:191-8. 2012..Early mortality rates remain high. Effective chemotherapy can result in reversal of organ dysfunction and recovery. Reductions in light chain production translate to improved survival... - Immunoglobulin D amyloidosis: a distinct entityMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 119:44-8. 2012..The overall survival of these patients does not appear to be different from that of patients who have light-chain amyloidosis associated with another monoclonal protein... - Relevant prognostic features of multiple myeloma and the new International Staging SystemMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 48:458-68. 2007..This review describes development of the International Staging System and details prognostic factors that may further our understanding of the biology of multiple myeloma... - Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 51:2181-7. 2010..001). The only predictor of survival was cardiac stage (p < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival... - SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalizationM A Gertz
Division of Hematology, Rochester, MN 55905, USA
Bone Marrow Transplant 46:956-61. 2011..The median hospital stay was 3.5 days shorter in the group not receiving growth factor. It is feasible and reasonable to perform autologous SCT for multiple myeloma without administering growth factors... - Management of cold haemolytic syndromeMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 138:422-9. 2007..This review of cold haemolytic syndromes describes new therapies and clinical strategies to determine a correct diagnosis... - Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete responseMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Haematologica 92:1415-8. 2007..001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival... - IgM amyloidosis: clinical features in therapeutic outcomesMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Clin Lymphoma Myeloma Leuk 11:146-8. 2011..IgM patients are older, have a higher prevalence of neuropathy, a lower incidence of cardiac involvement (lower troponin T and NT-proBNP), and a much lower level of the involved immunoglobulin free light chain... - Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosisMorie Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Lymphoma 49:36-41. 2008..Those with troponin T levels exceeding 0.06 microg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials... - Managing myeloma of the kidneyMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 48:221-2. 2007 - Transplantation for amyloidosisMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Curr Opin Oncol 19:136-41. 2007..We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature... - Managing monoclonal gammopathy-associated neuropathyMorie A Gertz
Division of Hematology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
Leuk Lymphoma 47:785-6. 2006 - Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvementMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Kidney Int 68:1464-71. 2005.... - When is myeloma, myeloma?Morie A Gertz
Mayo Clinic, Department of Hematology, Rochester, MN 55905, USA
Leuk Lymphoma 47:1452-3. 2006 - Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide inductionMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 115:2348-53; quiz 2560. 2010..5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy... - Current status of stem cell mobilizationMorie A Gertz
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 150:647-62. 2010..Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor... - AmyloidosisMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Best Pract Res Clin Haematol 18:709-27. 2005..This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy... 
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapyMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 106:2837-40. 2005..The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches...- Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphomaM A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Bone Marrow Transplant 45:1396-403. 2010..This usually unappreciated resource utilization associated with stem cell mobilization failure highlights the need for more effective mobilization strategies... - Waldenström macroglobulinemia: a review of therapyMorie A Gertz
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 79:147-57. 2005.... - Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and managementMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 86:411-6. 2011..Given WM’s natural history, reduction of complications will be a priority for future treatment trials... - A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group StudyM A Gertz
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Bone Marrow Transplant 34:149-54. 2004..3 months. Median survival has not been reached. Stem cell transplantation for selected patients with amyloidosis is feasible in a cooperative group setting. A multicenter phase 3 trial of high-dose therapy is indicated... - Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)M A Gertz
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Bone Marrow Transplant 40:989-93. 2007..Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL... - Troponin in hematologic oncologyMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Leuk Lymphoma 49:194-203. 2008.... - Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidneyMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Nephrol Dial Transplant 24:3132-7. 2009..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described... - Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosisMorie A Gertz
Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester MN, 55905, USA
Haematologica 93:1402-6. 2008..The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group... - Transplantation for IgM amyloidosis and IgM myelomaMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Clin Lymphoma Myeloma 9:77-9. 2009..IgM patients are older, and the amyloidosis cohort has a higher incidence of neuropathy and lower incidence of cardiac involvement by echocardiography and troponin T level... - Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:1131-8. 2008..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates... - Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myelomaM A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Bone Marrow Transplant 43:619-25. 2009..Our data suggested that CY damaged the microenvironment and slowed engraftment. By lengthening the period between the completion of apheresis and stem cell reinfusion, the microenvironment may recover and result in faster engraftment... - Primary systemic amyloidosisMorie A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Treat Options Oncol 3:261-71. 2002..Transplant is associated with unique morbidities not seen in the transplantation of patients with other hematologic malignancies... - New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progressionMorie A Gertz
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 49:2240-5. 2008..This review will focus in particular on Src-dependent signalling pathways, reflecting the expanding realisation of the critical and ubiquitous role of Src family kinases (SFKs) in normal and abnormal hematopoiesis... - Waldenström's macroglobulinemiaM A Gertz
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Oncologist 5:63-7. 2000..The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated... - Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trialMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 147:677-80. 2009..Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609... - What is the correct philosophy for the treatment of multiple myeloma?Morie A Gertz
Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 48:2298-9. 2007 - Caring (really) for patients who use alternative therapies for cancerMorie A Gertz
Division of Hematology and Internal Medicine and Area General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:125s-128s. 2003 - Current status of stem cell transplantation for multiple myelomaMorie A Gertz
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Treat Options Oncol 6:229-40. 2005..Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown... - Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Bone Marrow Transplant 34:1025-31. 2004..Methods are needed to reduce treatment-related toxicity so that more patients can receive full-dose conditioning chemotherapy... - Treatment of immunoglobulin light chain (primary or AL) amyloidosisMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Oncology (Williston Park) 25:620-6. 2011..The role of the recently introduced novel agents in management of amyloidosis is also reviewed... - Therapy for immunoglobulin light chain amyloidosis: the new and the oldMorie A Gertz
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
Blood Rev 18:17-37. 2004..Systemic chemotherapy would not be expected to have any beneficial effect on other forms of amyloid and carries significant risk... - Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myelomaDavid Dingli
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Clin Lymphoma Myeloma 6:384-8. 2006..0012 and P < 0.0001, respectively). CONCLUSION: We conclude that high-dose cyclophosphamide does not increase overall CR rates or improve TTP for patients with myeloma undergoing ASCT... - Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz
Mayo Clinic, Rochester, MN, USA
Semin Oncol 30:121-6. 2003..11) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism... - Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay
Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 115:1343-50. 2010..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results... - Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Haematologica 90:1650-4. 2005..INTERPRETATION AND CONCLUSIONS: The median time to disease progression in patients with multiple myeloma who receive initial therapy with Thal/Dex and who do not undergo ASCT is 18 months... - Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experienceAnita D'Souza
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 120:56-62. 2012..Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT... - Long-term outcome of autologous stem cell transplantation in light chain deposition diseaseElizabeth C Lorenz
Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
Nephrol Dial Transplant 23:2052-7. 2008..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD... - Myeloma and the newly diagnosed patient: a focus on treatment and managementS Vincent Rajkumar
Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
Semin Oncol 29:5-10. 2002..The role of supportive care strategies for patients with bone disease, such as the use of bisphosphonates, is also discussed... - Natural history and therapy of 66 patients with mixed cryoglobulinemiaAlan H Bryce
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 81:511-8. 2006..Treatment is generally directed at the underlying condition. Not all patients require treatment, and many can be followed and treated symptomatically... - Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng
Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
Cancer Res 67:2982-9. 2007..Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients... - Two-dimensional acoustic pattern derived strain parameters closely correlate with one-dimensional tissue Doppler derived strain measurementsKaren M Modesto
Division of Cardiology, Mayo Clinic College of Medicine, Rochester, MN, USA
Eur J Echocardiogr 7:315-21. 2006..Two-dimensional strain echocardiography may help to facilitate the routine clinical implementation of deformation analysis... - Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 85:737-40. 2010..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM... - Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor
Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Blood 114:518-21. 2009..These results need confirmation in larger, prospectively designed studies... - Vascular abnormalities in primary amyloidosisKaren M Modesto
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
Eur Heart J 28:1019-24. 2007..Primary amyloidosis (AL) is a systemic disease; however, there is limited information regarding the presence and character of vascular abnormalities... - Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:34-9. 2003..CONCLUSIONS: Thalidomide is useful in the treatment of patients with relapsed multiple myeloma and produced durable response in approximately one third of patients, with median response duration of nearly 1 year... - Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Blood 107:3384-8. 2006..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management... - Prognostic value of angiogenesis in solitary bone plasmacytomaShaji Kumar
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:1715-7. 2003..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma... - Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosisMichelle K Manske
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Clin Immunol 120:106-20. 2006..These data provide a robust example of the use of graphical quantification methods in delineating the role of neoplastic precursors in the pathogenesis of hematopoietic malignancies... - Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementR A Kyle
Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1121-7. 2010..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months... - Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myelomaSumit Madan
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 85:232-8. 2010..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)... - Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapiePrashant Kapoor
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 85:532-7. 2010..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents... - Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 85:664-9. 2010..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results... - Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myelomaGrzegorz S Nowakowski
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 106:2276-9. 2005..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival... - In vivo and in silico studies on single versus multiple transplants for multiple myelomaDavid Dingli
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Cancer Sci 98:734-9. 2007..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results... - Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myelomaCynthia X Ma
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 104:40-2. 2004..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process... - High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myelomaMorie A Gertz
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Expert Rev Anticancer Ther 6:343-60. 2006..Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy... - Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseasesNelson Leung
Divisions of Hematology and, Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, Departments of Biomedical Statistics and Informatics, Anatomic Pathology, and, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota
Clin J Am Soc Nephrol 7:1964-8. 2012.... - Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patientsMiguel A Park
Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Medicine (Baltimore) 82:291-8. 2003..Liver biopsy was safe. Some patients benefit from systemic chemotherapy... - Amyloidosis with IgM monoclonal gammopathiesMorie A Gertz
Dysproteinemia Clinic and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
Semin Oncol 30:325-8. 2003..We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival... - Waldenström's macroglobulinemia: a review of therapyMorie A Gertz
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 43:1517-26. 2002..Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenström's, and the patient's potential for developing toxic side effects of the selected treatment regimen... - Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyIrene M Ghobrial
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
Cancer 101:2593-8. 2004..Factors predicting an initial increase in IgM levels could not be identified... - Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:827-30. 2003..008). The prognostic value of circulating PBPCs may help select treatment for patients with AL... - Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 119:665-71. 2002..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy... - Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significanceShaji Kumar
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 23:5668-74. 2005.... - Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial
Division of Hematology, Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Br J Haematol 133:158-64. 2006..Beta2-microglobulin > or =4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM... - Clinical implication of centrosome amplification in plasma cell neoplasmWee J Chng
Division of Hematology-Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
Blood 107:3669-75. 2006.... - Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective studyHilmi Ege
Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
Br J Haematol 141:792-8. 2008..This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM... - Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay
Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
Eur J Haematol 85:200-8. 2010..The goal of this retrospective study was to compare the efficacy and toxicity of lenalidomide-dexamethasone (len/dex) vs. melphalan-prednisone-lenalidomide (MPR) as upfront therapy for newly diagnosed elderly patients with myeloma... - The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myelomaMustaqeem Siddiqui
Division of Hematology, Mayo Clinic, Rochester 55905, USA
Leuk Lymphoma 49:1436-51. 2008.... - The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaCheng E Chee
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 114:2617-8. 2009..2 years vs 2.3 years, respectively; P = .01)... - Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust
Division of Hematology, Mayo Clinic, Rochester, MN 55905
Mayo Clin Proc 84:114-22. 2009..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma... - The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisAngela Dispenzieri
Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
Blood 109:465-70. 2007..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation... - Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Am J Hematol 85:431-4. 2010..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders... - Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk scoreShaji K Kumar
Division of Hematology, Mayo Clinic, Rochester, MN 55905
Mayo Clin Proc 86:12-8. 2011..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL... - Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsAngela Dispenzieri
Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 85:757-9. 2010.... - Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresShaji Kumar
Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
Blood 116:5126-9. 2010..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL... - Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:21-33. 2003..To determine the clinical and laboratory features of newly diagnosed multiple myeloma... - Treatment of immunoglobulin light chain amyloidosisMorie A Gertz
Division of Hematology W10, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Curr Hematol Malig Rep 4:91-8. 2009..Virtually all patients are candidates for a trial of therapy, and it is possible to find a nontoxic regimen that can be administered to virtually any patient... - A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 85:409-13. 2010..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting... - Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 85:824-33. 2010..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease... - Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosisImran S Syed
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
JACC Cardiovasc Imaging 3:155-64. 2010.... - Thrombotic microangiopathy during peripheral blood stem cell mobilizationHarris V K Naina
Division of Hematology, Department of Internal Medicine, Mayo Clinic, College of Medicine, Rochester, Minnesota, USA
J Clin Apher 24:259-61. 2009..It is possible that GCSF may have directly (activating endothelial cells) or indirectly (activation of underlying autoimmune disorder) contributed to TMA in this patient... - Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalMartha Q Lacy
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 84:799-802. 2009..This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma... - Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 84:1095-110. 2009..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence... - A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL)Morie A Gertz
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Amyloid 9:24-30. 2002..4'-Iodo-4'-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results... - Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantationMartha Q Lacy
Division of Hematology and Internal Medicine, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
Arch Dermatol 141:1277-82. 2005..Herein we describe a novel therapeutic approach. Because autologous hematopoietic stem cell transplantation is effective in other plasma cell proliferative disorders, it may be effective in this setting... - Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 106:4050-3. 2005..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma... - Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosisNelson Leung
Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
Am J Kidney Dis 46:270-7. 2005..This study was undertaken to determine the prognostic importance of renal response after high-dose melphalan and stem cell transplantation... - Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvementNelson Leung
Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic and Foundation, Rochester, MN, USA
Am J Transplant 5:1660-70. 2005..This experience supports the feasibility of sequential living donor KTx and autologous SCT for carefully selected patients with ESRD due to AL...
Research Grants
- Phase 3 stem cell transplant for light chain amyloidosisMorie Gertz; Fiscal Year: 2007..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
- Phase 3 stem cell transplant for light chain amyloidosisMorie Gertz; Fiscal Year: 2009..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
- Phase 3 stem cell transplant for light chain amyloidosisMorie A Gertz; Fiscal Year: 2010..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
- Phase 3 stem cell transplant for light chain amyloidosisMorie A Gertz; Fiscal Year: 2011..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..